Inception Return
(9/23/2005)
|
1.52 %
|
|
YTD Return
|
8.00 %
|
|
NAVPS
(9/20/2018)
|
$10.98
|
|
Change
|
($0.01) / -0.11 %
|
|
|
Growth of $10,000
(As of August 31, 2018)
|
|
MER
|
1.31 %
|
|
Assets ($mil)
|
$2.72
|
|
Rank (1Yr)
|
-
|
|
Std Dev (3Yr)
|
14.93 %
|
|
Volatility Ranking (3Yr)
|
10/10
|
|
RRSP Eligibility
|
Yes
|
|
Load
|
No Load
|
|
Max Front End
|
-
|
|
Max Back End
|
-
|
|
Sales Status
|
Open
|
|
|
Objective
The Fund's objective is to provide long-term growth of capital by investing primarily in the securities markets of Europe considered by the Manager to be undervalued. Investments may be made in securities markets outside of Europe. Investments may include common and preferred shares, convertible debentures, government and corporate bonds and short-term indebtedness.
|
Management Co.
Chou Associates Management Inc.
Managers
Francis Chou
|
|
Asset Allocation
(As of June 30, 2018)
|
Sector Allocation
(As of June 30, 2018)
|
Geographic Allocation
(As of June 30, 2018)
|
Top 10 Holdings
| Name | Asset | Sector | Geographic | Percent |
| Bank of Ireland Group plc | International Equity | Financial Services | European Union | 16.87% |
| Sanofi SA - ADR | International Equity | Healthcare | European Union | 15.26% |
| Endo International PLC | International Equity | Healthcare | European Union | 14.39% |
| Intralot Integrated Lottery Sys Srvcs SA | International Equity | Technology | European Union | 11.39% |
| Ryanair Holdings PLC | International Equity | Industrial Services | European Union | 9.97% |
| Abbey PLC | International Equity | Industrial Goods | European Union | 9.88% |
| CAD SWEEP VII CIBC MELLON 0.50% 31-Dec-2049 | Cash and Equivalents | Cash and Cash Equivalent | Canada | 9.67% |
| Teva Pharmaceutical Industries Ltd - ADR | International Equity | Healthcare | Africa and Middle East | 6.96% |
| Eurobank Ergasias SA | International Equity | Financial Services | European Union | 4.98% |
| USD SWEEP VII CIBC MELLON 1.00% 31-Dec-2049 | Domestic Bonds | Fixed Income | Canada | 0.67% |
Performance Data
(As of August 31, 2018)
|
|
Return (%)
|
Annualized Return (%)
|
|
Return
|
1
Mth
|
3
Mth
|
6
Mth
|
YTD
|
1
Yr
|
3
Yr
|
5
Yr
|
10
Yr
|
|
Fund
|
0.59
|
8.41
|
3.49
|
8.00
|
7.68
|
-4.53
|
1.08
|
4.32
|
|
Benchmark
|
-2.29
|
0.69
|
0.11
|
1.56
|
7.58
|
6.09
|
10.36
|
5.86
|
|
Quartile Ranking
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Calendar Return (%)
|
2017
|
2016
|
2015
|
2014
|
2013
|
2012
|
2011
|
2010
|
2009
|
2008
|
|
Fund
|
4.28
|
-18.05
|
2.49
|
1.60
|
41.35
|
27.26
|
-4.89
|
-0.30
|
35.28
|
-43.67
|
|
Benchmark
|
18.15
|
-3.54
|
17.20
|
3.06
|
35.86
|
17.02
|
-9.65
|
-0.64
|
18.93
|
-34.99
|
|
Quartile Ranking
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
MSCI ESG Fund Metrics (As of September 01, 2018)
|
The MSCI ESG Quality Score measures the ability of underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors.
|
|
The percentage of the portfolio's market value exposed to companies flagged for one or more standard SRI exclusion factors (alcohol, civilian firearms, gambling, weapons, cluster bombs, landmines, nuclear power, GMOs, and tobacco).
|
The portfolio weighted average of each company’s percent of revenue generated by Sustainable Impact Solutions (goods and services that address at least one of the world’s social and environmental challenges), as defined by the United Nations Sustainable Development Goals.
|
ESG data provided by MSCI
MSCI ESG Research LLC’s (“MSCI ESG”) Fund Metrics products (the “Information”) provide environmental, social and governance data with respect to underlying securities within more than 23,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided “as is” and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.